Low Bone Mass Clinical Trial
Official title:
Resveratrol for the Prevention of Bone Loss in Postmenopausal Women
The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.
34 women will be randomly assigned to two groups: 1) the placebo group and 2) the resveratrol group. The resveratrol group will receive 500 mg resveratrol daily for 24 weeks, and placebo group will receive placebo pills. Both groups will receive 500 mg calcium plus 400 IU vitamin D daily. Blood and urinary biomarkers of bone metabolism will be assessed at baseline and after 12 and 24 weeks intervention. Bone mineral density will be assessed using dual-energy X-ray absorptiometry at baseline and after 24 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00980174 -
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
|
Phase 3 | |
| Completed |
NCT00887965 -
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
|
Phase 2 | |
| Completed |
NCT00890981 -
A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
|
Phase 3 | |
| Active, not recruiting |
NCT03227458 -
DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women
|
N/A |